Literature DB >> 23183241

[Mesenchymal stem cell therapy in heart disease].

João Pedro Lopes1, António Fiarresga, Pedro Silva Cunha, Joana Feliciano, Rui Cruz Ferreira.   

Abstract

Cardiovascular disease is among the main causes of mortality and morbidity worldwide. Despite significant advances in medical and interventional therapy, the prognosis of conditions such as ischemic heart disease is still dismal. There is thus a need to investigate new therapeutic tools, one of which is stem cell therapy. Hematopoietic stem cells are the most studied type, and the fact that their biology is relatively well understood has led to their being used in preclinical research and clinical trials. However, the results of some of these studies have been controversial, which has opened the way for studies on other cell types, such as mesenchymal stem cells. These cells have immunomodulatory properties which suggest that they have therapeutic potential in cardiology. In the present article, the authors review the state of the art regarding mesenchymal stem cells, from basic and translational research to their use in clinical trials on ischemic heart disease, heart failure and arrhythmias, and discuss possible future uses.
Copyright © 2012 Sociedade Portuguesa de Cardiologia. Published by Elsevier España. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23183241     DOI: 10.1016/j.repc.2012.05.014

Source DB:  PubMed          Journal:  Rev Port Cardiol        ISSN: 0870-2551            Impact factor:   1.374


  4 in total

1.  Sry-type HMG box 18 contributes to the differentiation of bone marrow-derived mesenchymal stem cells to endothelial cells.

Authors:  Izuagie Attairu Ikhapoh; Christopher J Pelham; Devendra K Agrawal
Journal:  Differentiation       Date:  2015-04-23       Impact factor: 3.880

2.  Intracoronary Delivery of Human Mesenchymal/Stromal Stem Cells: Insights from Coronary Microcirculation Invasive Assessment in a Swine Model.

Authors:  António Fiarresga; Márcia F Mata; Sandra Cavaco-Gonçalves; Mafalda Selas; Irina N Simões; Eunice Oliveira; Belmira Carrapiço; Nuno Cardim; Joaquim M S Cabral; Rui Cruz Ferreira; Cláudia L da Silva
Journal:  PLoS One       Date:  2015-10-19       Impact factor: 3.240

3.  Activation of NRG1-ERBB4 signaling potentiates mesenchymal stem cell-mediated myocardial repairs following myocardial infarction.

Authors:  X Liang; Y Ding; Y Zhang; Y-H Chai; J He; S-M Chiu; F Gao; H-F Tse; Q Lian
Journal:  Cell Death Dis       Date:  2015-05-21       Impact factor: 8.469

4.  Association of TNF-α with impaired migration capacity of mesenchymal stem cells in patients with systemic lupus erythematosus.

Authors:  Linyu Geng; Xia Li; Xuebing Feng; Jiyun Zhang; Dandan Wang; Jinyun Chen; Rui Liu; Haifeng Chen; Lingyun Sun
Journal:  J Immunol Res       Date:  2014-11-24       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.